Evidence map›Paper›PMID 41657941›Full record

ArticleLymphatics2026

EBV-Driven NK/T-Cell Lymphoproliferative Disorders: Clinical Diversity and Molecular Insights.

Aleksander Luniewski, Sahil Chaudhary, Adam Goldfarb, Ifeyinwa E Obiorah

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lymphatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07727083 (A Multicenter Ambidirectional Clinical and Biological Cohort Study of Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Diseases), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07727083 recruitingnot on this map

A Multicenter Ambidirectional Clinical and Biological Cohort Study of Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Diseases

Typeobservational_patient_registrySponsorRong TaoRan2026 to 2035Enrolled1,500ConditionsExtranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia, Systemic Chronic Active Epstein-Barr Virus Disease, Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aleksander LuniewskiSection of Hematopathology, Department of Pathology, University of Virginia Health, 1215 Lee Street, Charlottesville, VA 22903, USA.
Sahil ChaudharySection of Hematopathology, Department of Pathology, University of Virginia Health, 1215 Lee Street, Charlottesville, VA 22903, USA.
Adam GoldfarbSection of Hematopathology, Department of Pathology, University of Virginia Health, 1215 Lee Street, Charlottesville, VA 22903, USA.
Ifeyinwa E ObiorahSection of Hematopathology, Department of Pathology, University of Virginia Health, 1215 Lee Street, Charlottesville, VA 22903, USA.

Funding

Nqo2 in Primaquine-Induced Hemolysis of G6PD-deficient RBCsR01HL172874 · NHLBI · UNIVERSITY OF VIRGINIA · PI Adam N. Goldfarb · 2024 to 2026
$2.2M
NHLBI NIH HHS R01 HL172874
6 · The paper itself

Abstract

The World Health Organization (WHO) and International Consensus Classification (ICC) systems have classified EBV-positive NK/T-cell neoplasms in adults and EBV-positive T/NK-cell lymphoid lymphoproliferative disorders (LPD) in children. Recent molecular profiling techniques have revealed the pathogenesis of these disorders, showing interactions among EBV-encoded proteins, host immune responses, and genetic alterations. Extranodal NK/T-cell lymphoma (ENKTL) shows molecular diversity, with various subtypes (TSIM, MB, and HEA) identified through a multiomics approach. Aggressive NK-cell leukemia (ANKL) has mutations in JAK/STAT, epigenetic regulators, and

Indexed as

EBVlymphomalymphoproliferative disordermolecularNK/T cell

Identifiers

PMID41657941
PMCPMC12880704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.